Beckman Coulter Life Sciences and Apostle announce exclusive liquid biopsy partnership

Today, at the Advances in Genome Biology and Technology (AGBT) General Meeting, Beckman Coulter Life Sciences announces the launch of Apostle MiniMaxTM High Efficiency Cell-Free DNA Isolation Kit through an exclusive partnership with Apostle, a liquid biopsy company. As cfDNA workflows move beyond theoretical and into human health applications, Apostle's industry-leading chemistry paired with Beckman Coulter Life Sciences’ portfolio of genomic reagents and liquid handling platforms enables researchers to meet the growing demands for sequencing of tumor-derived cfDNA.

Surpassing industry standards for yield and purity of cfDNA, Apostle MiniMax is a magnetic nanoparticle-based kit to extract cfDNA from plasma using manual or automated workflows. Due to limited cfDNA concentration, sufficient yield for next-generation sequencing (NGS) or other downstream applications can require higher volumes of plasma. As the volume increases, issues such as recovery efficiency and workflow complexity often arise. Plasma contains a host of contaminants that are problematic at this scale and can reduce assay sensitivity. Apostle MiniMax technology performs reliably across a range of volume inputs, consistently recovering high quantities of cfDNA, while effectively removing contaminants.

Beckman Coulter Life Sciences is committed to working collaboratively with our customers to find the best technologies to meet their complex needs.

We have listened to their ongoing challenges in working with cfDNA and sought to find ways to effectively combat those issues. This includes recognizing that an innovative product from a startup like Apostle is the best technology to address these needs."

Steve Wowk, Director of Genomics, Beckman Coulter Life Sciences

Beckman Coulter Life Sciences’established global presence and commitment to life sciences makes them an ideal collaborator to provide access to our innovative nucleic acid isolation products to customers around the globe."

David Ge, President and CEO, Apostle Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Beckman Coulter Life Sciences - Automation and Genomics. (2019, March 04). Beckman Coulter Life Sciences and Apostle announce exclusive liquid biopsy partnership. News-Medical. Retrieved on May 24, 2019 from https://www.news-medical.net/news/20190304/Beckman-Coulter-Life-Sciences-and-Apostle-announce-exclusive-liquid-biopsy-partnership.aspx.

  • MLA

    Beckman Coulter Life Sciences - Automation and Genomics. "Beckman Coulter Life Sciences and Apostle announce exclusive liquid biopsy partnership". News-Medical. 24 May 2019. <https://www.news-medical.net/news/20190304/Beckman-Coulter-Life-Sciences-and-Apostle-announce-exclusive-liquid-biopsy-partnership.aspx>.

  • Chicago

    Beckman Coulter Life Sciences - Automation and Genomics. "Beckman Coulter Life Sciences and Apostle announce exclusive liquid biopsy partnership". News-Medical. https://www.news-medical.net/news/20190304/Beckman-Coulter-Life-Sciences-and-Apostle-announce-exclusive-liquid-biopsy-partnership.aspx. (accessed May 24, 2019).

  • Harvard

    Beckman Coulter Life Sciences - Automation and Genomics. 2019. Beckman Coulter Life Sciences and Apostle announce exclusive liquid biopsy partnership. News-Medical, viewed 24 May 2019, https://www.news-medical.net/news/20190304/Beckman-Coulter-Life-Sciences-and-Apostle-announce-exclusive-liquid-biopsy-partnership.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Courtagen announces acquisition of Medicinal Genomics